期刊
MOLECULAR CANCER
卷 13, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1476-4598-13-55
关键词
Castration-resistant; Prostate cancer; Epithelial-to-mesenchymal transition; Cancer stem cells; Signaling pathways
资金
- Chinese Ministry of Science and Technology [2012CB966800, 2013CB945600, 2012CB967900]
- National Natural Science Foundation of China [81130038, 81372189]
- Science and Technology Commission of Shanghai Municipality
- Shanghai Education Committee Key Disciplines and Specialties Foundation [J50208]
- Shanghai Health Bureau Key Disciplines and Specialties Foundation
- KC Wong foundation
- Shanghai Jiao Tong University School of Medicine Doctor Innovation Foundation [BXJ201217]
An important clinical challenge in prostate cancer therapy is the inevitable transition from androgen-sensitive to castration-resistant and metastatic prostate cancer. Albeit the androgen receptor (AR) signaling axis has been targeted, the biological mechanism underlying the lethal event of androgen independence remains unclear. New emerging evidences indicate that epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) play crucial roles during the development of castration-resistance and metastasis of prostate cancer. Notably, EMT may be a dynamic process. Castration can induce EMT that may enhance the stemness of CSCs, which in turn results in castration-resistance and metastasis. Reverse of EMT may attenuate the stemness of CSCs and inhibit castration-resistance and metastasis. These prospective approaches suggest that therapies target EMT and CSCs may cast a new light on the treatment of castration-resistant prostate cancer (CRPC) in the future. Here we review recent progress of EMT and CSCs in CRPC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据